0.00Open0.98Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover6249.96%IV-22.61%PremiumMay 17, 2024Expiry Date0.39Intrinsic Value100Multiplier-5DDays to Expiry0.59Time Value100Contract SizeAmericanOptions Type-0.6234Delta0.3330Gamma2.66Leverage Ratio-9.1936Theta0.0000Rho-1.66Eff Leverage0.0001Vega
Acurx Pharmaceuticals Stock Discussion
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
Dow Jones· 7 mins ago
2 MINUTES AGO, 7:00 AM EST
VIA PR NEWSWIRE
4 MINUTES AGO, 7:01 AM EST
VIA PR NEWSWIRE
No comment yet